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Abstract
Background: Peroxisome proliferator-activated receptor (PPAR)γ is a key regulator in adipose tissue.
The rare variant Pro12Ala of PPARγ2 is associated with a decreased risk of insulin resistance. Being dietary
PPARγ ligands, conjugated linoleic acids (CLAs) received considerable attention because of their effects on
body composition, cancer, atherosclerosis, diabetes, obesity and inflammation, although some effects were
only demonstrated in animal trials and the results in human studies were not always consistent. In the
present study effects of CLA supplementation on genome wide gene expression in adipose tissue biopsies
from 11 Ala12Ala and 23 Pro12Pro men were investigated. Subjects underwent four intervention periods
(4 wk) in a randomized double blind cross-over design receiving 4.25 g/d of either cis-9, trans-11 CLA,
trans-10,cis-12 CLA, 1:1 mixture of both isomers or a reference linoleic acid oil preparation. After each
intervention biopsies were taken, whole genome expression microarrays were applied, and genes of
interest were verified by realtime PCR.
Results: The following genes of lipid metabolism were regulated by CLA: LDLR, FASN, SCD, FADS1 and
UCP2 were induced, while ABCA1, CD36 and CA3 were repressed. Transcription factors PPARγ,
NFAT5, CREB5 and EBF1, the adipokine NAMPT, members of the insulin signaling cascade SORBS1 and
IGF1 and IL6ST were repressed, while the adipokine THBS1 and GLUT4 involved in insulin signaling were
induced. Compared to trans-10,cis-12 CLA and the CLA mixture the cis-9, trans-11 CLA isomer exerted
weaker effects. Only CD36 (-1.2 fold) and THBS1 (1.5 fold) were regulated. The CLA effect on expression
of PPARγ and leptin genes depends on the PPARγ2 genotype.
Conclusion: The data suggest that the isomer specific influence of CLA on glucose and lipid metabolism
is genotype dependent and at least in part mediated by PPARγ.
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Introduction
The term CLA describes a group of 18-carbon fatty acids
with 2 conjugated double bonds. They are formed as a
result of enzymatic hydrogenation of linoleic acid in
ruminants and found in lipids of tissue and milk. Of the
various isomers, cis-9, trans-11 (c9t11) CLA is most pre-
dominant in food. In CLA preparations c9t11 CLA and
trans-10, cis-12 (t10c12) CLA are the prevailing isomers.
CLAs received considerable attention because of their
effect on body weight, muscle mass and glucose homeos-
tasis [1,2] in certain animal models. In humans evidence
is less clear. CLA supplementation was shown to have sig-
nificant favorable effects on body weight and fat mass
[3,4] while results on other risk markers are still conflict-
ing. The findings showed great variability, which may be
partly explained by the length of the studies and the dos-
age, but also due to differences in the isomer mixtures
used for supplementation. Additionally, the genetic back-
ground of individuals may have contributed to the varia-
bility of the results.
The PPARγ2 gene is a member of the nuclear receptor
super family and is highly expressed in adipose tissue [5].
Indeed, the receptor plays a critical role in adipocyte dif-
ferentiation and regulates insulin sensitivity by transcrip-
tionally activating adipocyte-specific genes involved in
insulin signaling, glucose uptake, fatty acid uptake and
lipid-storage. A single nucleotide polymorphism (SNP) in
the PPARγ2 results in a proline to alanine substitution and
has been associated with lower risk for type 2 diabetes,
higher insulin sensitivity, but paradoxically weight gain
[6]. The polymorphism of PPARγ2 was shown to affect
metabolic responses to dietary fat [7,8]. CLAs are natural
PPAR-ligands [9]. Only one report is available which pro-
vides data on the CLA influence on gene expression in
human adipose tissue [10].
To our knowledge this is the first human study using a
microarray based genome wide gene expression screening
to evaluate isomer specific CLA effects in human adipose
tissue. In this study we further investigated whether CLA
effects depend on the Pro12Ala polymorphism.
Methods
Subjects
38 subjects (45-68 years old) were recruited from a popu-
lation based cohort (n = 1558) in Kiel (MICK, Metabolic
Intervention Cohort Kiel) which has been previously
described [11]. 15 male PPARγ2 Ala12Ala homozygous
and 23 BMI-matched homozygous control subjects
(PPARγ2 Pro12Pro) were included. Exclusion criteria
were: metabolic or gastrointestinal diseases, drug therapy
affecting gastrointestinal metabolism, and previously
diagnosed diabetes according to WHO criteria (WHO,
2006). The intervention study was mono-centered and
followed a randomized, placebo-controlled, double
blind, cross over design. After written consent, 38 men
randomly underwent four intervention periods, consum-
ing soft gel capsules with either c9t11 CLA, t10c12 CLA, a
commercially available mixture of both CLA isomers or
placebo (linoleic acid from safflower oil) as free fatty
acids; resulting in a total of 4.25 g/d fatty acids, containing
either 3.40 g of the individual isomers or CLA mixture
active substance or 3.23 g linoleic acid. Study participants
completed four intervention periods lasting 28 days each;
separated by wash-out phases lasting 42 days. The study
protocol was approved by the local ethics committee of
the Christian-Albrechts-Universität (Kiel, Germany).
Sampling
After each intervention subcutaneous abdominal adipose
tissue biopsies were performed under local anaesthesia by
aspiration from the peri-umbilical area, through a Meng-
hini-needle. Subcutaneous adipose tissue was immedi-
ately flash-frozen in liquid nitrogen for later analysis. BMI
(body mass index), waist and hip circumference, blood
pressure, plasma glucose and insulin, triacylglycerols,
LDL-cholesterol HDL-cholesterol and HOMA-IR (home-
ostasis model assessment-insulin resistance) calculated as
[(fasting insulin μU/ml × fasting glucose mg/dl)/405]
were assessed after each intervention. Multiple ANOVA
was used to compare effects of the 4 dietary interventions.
RNA
RNA was extracted using Ambion kit according to the
manufacturer's protocol for fatty tissue. RNA quality was
verified by spectrophotometry (260:280 ratio) and by Bio
analyzer (Agilent).
Microarray
Global gene expression was analyzed with microarray
technology using the Affymetrix Human Genome U133
2.0 Plus according to the manufacturer's protocol and the
Gene Chip Set, covering more than 54 000 gene tran-
scripts, corresponding to almost 22 000 genes. Expression
values were calculated using the robust multi-array aver-
age algorithm [12] and were statistically analyzed for dif-
ferential gene expression adjusting all P-values for false
discovery-rate correction. The positive and negative con-
trols met the expected values (data not shown). Wilcoxon
test followed by Benjamini Hochberg Correction as post
hoc test for multiple testing was used to analyse signifi-
cant differences compared to intervention with linoleic
acid, and Westfall and Young permutation was used for
cut off calculation [13]. Pathway members were analysed
by Ingenuity Pathway Analysis® (Ingenuity Systems, http:/
/www.ingenuity.com) software.Lipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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RT-PCR
Purified RNA was reverse transcribed using Applied Bio-
systems High Capacity cDNA Reverse Transcription Kit
according to manufacturer's recommendations. Realtime
PCR was performed using an ABI Prism 7900 HT
Sequence Detection System with TaqMan® Low-Density
Arrays, which is a 384-well micro-fluidic card pre-loaded
with optimised probes and primers for selected genes. Rel-
ative quantification analysis was performed with ABI
Prism SDS 2.1.1 software. The endogenous control TAF10
(TAF10 RNA polymerase II) was used to normalize the
differences in amounts of the cDNAs added. Normalized
delta (Δ) cycle threshold (CT) values were then subjected
to evaluation of statistical significance (p < 0.05) of differ-
ential expression compared to control using the Wilcoxon
test. Fold changes were calculated using the ΔΔCT
method, whereby linoleic acid intervention values were
used as reference (control).
Results
37 out of 38 men completed the study. Data were based
on 34 subjects; one dropped out because he fell ill and
three subjects with PPARγ2 Pro12Pro SNP were excluded
because they showed elevated fasting glucose levels
according to the WHO criteria during most or all interven-
tions. No significant changes in anthropometric character-
istics and fasting values were detected after any
intervention (Table 1).
From five PPARγ2 Ala12Ala subjects and five BMI-
matched Pro12Pro control subjects' microarray analyses
were made after each intervention. The data have been
deposited in NCBI's Gene Expression Omnibus and are
accessible through GEO Series accession number
GSE16615. The experiment showed the presence of
approximately 12 000 gene transcripts in subcutaneous
adipose tissue, belonging to about 1200 different genes.
According to Wilcoxon test at p < 0.05, 310 genes were
changed by the CLA preparations as compared to the con-
trol intervention. After Benjamini Hochberg Correction as
post hoc test for multiple testing no intervention showed
significant effects.
According to Westfall and Young permutation the cut off
for a significant difference in gene expression between
CLA and control intervention was set at +/- 1.51 fold
change. Among the genes exceeding this limit only those
were further evaluated that were detected on all microar-
rays, showed annotated gene symbols and resulted in no
hypothetical proteins. Following these criteria 1020 gene
transcripts were differently expressed after CLA interven-
tion compared to the control (Figure 1).
The expression of 42 genes was verified by realtime PCR
after all interventions in all subjects. The criteria for gene
selection were as follows: they showed a strong difference
in the expression after one or more CLA interventions
compared to the control in microarray analysis, they
showed a different expression between the two genotype
groups after an intervention, they are a member of a regu-
lated pathway (pathway analysis with Ingenuity Pathway
Analyses™) or they were previously described to be regu-
lated by CLA.
Table 2 shows genes that were significantly regulated after
CLA interventions (p < 0.05) or showed a strong tendency
to be regulated (more than +/- 1.51 fold change and p ≤
0.1).
Discussion
To elucidate the mechanism of different effects exerted by
individual CLA isomers and the mixture of both CLA iso-
Table 1: Anthropometric characteristics, fasting values of all subjects (n = 34) at the end of each intervention period. 
Preparation linoleic acid CLA MIX cis-9,trans-11 CLA trans-10,cis-12 CLA P
Weight (kg) 84.2 (± 2.0) 84.2 (± 2.0) 84.1 (± 2.0) 84.0 (± 2.0) 0.851
BMI (kg/m2) 26.1 (± 0.5) 26.1 (± 0.4) 26.0 (± 0.4) 26.0 (± 0.5) 0.900
Waist (cm) 102.1 (± 1.5)a 102.1 (± 1.6)a 102.3 (± 1.5) a 101.2 (± 1.5) b 0.072
Hip (cm) 104.8 (± 1.0) 104.8 (± 1.0) 104.8 (± 1.0) 104.0 (± 1.0) 0.824
Waist/hip ratio 0.97 (± 0.01) 0.97 (± 0.01) 0.98 (± 0.01) 0.97 (± 0.01) 0.645
Plasma glucose (mg/dl) 96.5 (± 1.4) 98.2 (± 1.5) 97.5 (± 1.5) 96.5 (± 1.4) 0.487
HOMA-IR 3.0(± 0.3) 3.2(± 0.2) 3.1(± 0.3) 2.9(± 0.2) 0.693
Triacylglycerols (mg/dl) 127.0 (± 10.1) 119.1 (± 8.9) 124.4 (± 10.8) 124.7 (± 10.6) 0.787
Total cholesterol (mg/dl) 223.9(± 7.3) 225.3(± 6.8) 223.6(± 7.2) 226.5(± 6.8) 0.783
LDL cholesterol (mg/dl) 56.3(± 2.6) 56.5(± 2.3) 56.7(± 2.5) 54.6(± 2.8) 0.268
HDL cholesterol (mg/dl) 145.4(± 6.0) 143.1(± 5.8) 145.7(± 6.3) 146.4(± 5.7) 0.772
SBP (mmHg) 127 (± 3) 127 (± 3) 128 (± 3) 126 (± 2) 0.901
DBP (mmHg) 80(± 2) 79 (± 2) 80 (± 2) 80 (± 2) 0.871
Values are expressed as mean ± SEM. CLA, conjugated linoleic acid; BMI, body mass index, DBP diastolic Blood pressure, SBP systolic blood 
pressure LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, HOMA-IR; homeostasis model assessment-insulin 
resistance, intervention-dependent changes were compared using multiple ANOVA.Lipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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mers, a stepwise approach was applied. Following a
hypothesis free approach by human genome wide gene
expression screening, expression was verified by realtime
PCR in those genes which showed measurable differences
in expression compared to control intervention in the
microarray experiment, which are members of relevant
pathways or which were described in the literature as
being regulated by CLA. Not all microarray results from a
subgroup of five respectively ten persons could be verified
for the whole study group by realtime PCR.
Microarray results indicated that single isomers and the
CLA mixture of both isomers may modulate different
genes. This was also confirmed by the results of realtime
PCR (table 2). This may be due to the given structural dif-
ferences between these isomers and due to the fact that
more than one biochemical mechanism is supposedly
involved in their specific effects.
Fatty acid transport and metabolism
Microarray analyses showed that ABCA9  (ATP-binding
cassette, sub-family A, member 9) was much less
expressed after CLA interventions in the 10 selected sub-
jects. Verification for all 34 study subjects with realtime
PCR confirmed this result for the CLA mixture and the
t10c12 CLA intervention and showed genotype specific
effects.
Little is known about the physiological function of
ABCA9 especially in adipose tissue. ABCA9 is a member of
the ABCA6-like transport subclass, which is regulated by
cholesterol in an opposite direction than ABCA1 [14]. In
human macrophages, ABCA9 mRNA is induced during
monocyte differentiation and inhibited by cholesterol
influx in human macrophages, indicating that ABCA9 is a
cholesterol-responsive gene [15]. Lower expression in adi-
pose tissue after CLA mixture and t10c12 CLA interven-
tion (Table 2) may be due to high influx of cholesterol in
adipocytes, however, total plasma cholesterol did not
change after any CLA treatment (table 1).
The LDLR (LDL receptor) regulates plasma LDL choles-
terol levels. Yu-Poth et al. showed that CLA mixture
induces LDLR expression in the HepG2 hepatic cell line
[16]. Others found the strongest enhancing effect on
LDLR expression in mouse liver after t10c12 CLA admin-
istration compared to linoleic acid, whereas c9t11 CLA
showed no effect [17]. We also found a higher expression
after CLA mixture and t10c12 CLA treatment (table 2).
This effect was particularly found in Pro12Pro carriers.
These results suggest that CLA may up-regulate LDLR gene
expression to promote the clearance of LDL cholesterol
from circulation. By that it may have inhibited ABCA9
expression (table 2). The observed effects of CLA on
plasma lipids and particularly LDL-cholesterol in humans
are conflicting. We found, however, no significant effects
on plasma LDL or HDL cholesterol or triacylglycerol con-
centrations in our study (table 1).
CD36, another lipid transporter and scavenger receptor
for oxidized LDL, was less expressed after c9t11 and
t10c12 CLA treatment in all subjects. Lower expression of
CD36 after t10c12 CLA incubation were also detected in
mice 3T3-L1 cells [18]. Higher expression of LDLR and
lower expressions levels of CD36 after t10c12 CLA treat-
ment may be indicative of compensatory effects. Accord-
ingly, LDLR-/- mice had higher CD36 expression [19].
Plasma glucose levels play an important role in the regu-
lation of CD36 expression in adipose tissue [20]. Moreo-
ver, CD36 expression in subcutaneous adipose tissue was
higher in type 2 diabetic subjects [21]. Ala12Ala carriers in
particular showed significantly lower CD36 expression
after the intervention with the single CLA isomers (table
2).
An explanation may be provided by an electrophoretic
mobility shift assay experiment which showed that the
PPARγ2 Ala-variant binds with lower affinity to an PPARγ-
responsive element than the Pro-variant [22]. A reduced
transcription of specific PPARγ target genes was reported
for cells over-expressing the Ala-variant compared to Pro-
variant over-expressing cells [22].
Distribution of the gene transcripts (n = 1020) regulated  more than +/- 1.5 fold after the various interventions com- pared to linoleic acid control as assessed by whole genome  gene expression microarray U133 2.0 Plus GeneChip Figure 1
Distribution of the gene transcripts (n = 1020) regu-
lated more than +/- 1.5 fold after the various inter-
ventions compared to linoleic acid control as 
assessed by whole genome gene expression microar-
ray U133 2.0 Plus GeneChip. Intersections show genes 
regulated by more than one treatment.Lipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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LIPE (hormone sensitive lipase) is a key enzyme in mobi-
lization of fatty acids from intracellular lipid stores and is
a PPARγ target gene in human liver cells [23]. It was 1.96
fold more expressed after CLA mixture (p = 0.06) and 1.8
fold more after t10c12 CLA (p = 0.09) treatment in the
rare allele carriers. This does not support the findings from
Nazare et al., who found a significantly lower expression
of LIPE after a 14-week supplementation with CLA mix-
ture in human adipose tissue [10], whereas lipoprotein
lipase was not affected in their study. In contrast, in male
Syrian Golden hamsters there was no effect on LIPE in adi-
pose tissue after 3 weeks with a t10c12 CLA enriched diet
[24].
CA3 (carbonic anhydrase 3) hydrates carbon dioxide to
yield bicarbonate and carbohydrogen ion and has a vari-
ety of physiological functions. One is to provide bicarbo-
nate ions necessary to convert acetyl-CoA into malonyl-
Table 2: Fold change (median) of genes after 4 weeks intervention with a mixture of c9t11 and t10c12 CLA, c9t11 CLA, and t10c12 
CLA compared to control (LA) according to realtime PCR verification.
MIX C9T11 CLA T10c12 CLA
Gene symbol [NCBI RefSeq] all Pro Ala all Pro Ala all Pro Ala
Fatty acid transport and metabolism PPARγ dependency
ABCA9 [NM_080283.3] -1.3* -1.3* -1.4* n/a
LDLR [NM_000527.3] 1.2** 1.8** 1.5** 1.5** ↑[85]
CD36 [NM_001001547.1] -1.2* -1.6* -1.3* -1.2* ↑[65,86]
LIPE [NM_005357.2]1 . 9 6 †1 . 8 † ↑[23]
CA3 [NM_005181.2] -2.0** -2.0* n/a
FASN [NM_004104.4] 1.5* 1.2* 1.4* ↑[87]
SCD [NM_005063.4] 1.3* 1.5* 1.9* ↑[34,88]
FADS1 [NM_013402.3] 1.6* 1.6* n/a
Transkription factors
PPARG [NM_138711.3] -1.4**a 1.3 b
NFAT5 [NM_138713.2] -1.5* -1.6* -1.6* -1.9† n/a
CREB5 [NM_182899.3] -1.5* -1.9† n/a
EBF1 [NM_024007.3]- 1 . 5 † ↑[89]
Adipokines
ADIPOQ [NM_004797.29] 1.6† 1.5† ↑[90,91]
LEP [NM_000230.2]- 1 . 2  a 1 . 7 † b ↓[92]
NAMPT [NM_005746.2] -1.6* = [62]
THBS1 [NM_003246.2] 1.5** 1.3* 1.5* ↓[64] ↑[65]
Insulin signaling
IGF1 [NM_001111284.1] -1.5† -1.2** -1.2* ↓ [93]
SLC2A4 [NM_001042.2] 1.3* 1.5† ↑[94]
SORBS1 [NM_001034954.1]- 1 . 2 * ↑[74]
PIK3R1 [NM_181523.1]- 1 . 6 † ↑[95]
Others
HPGD [NM_000860.3] -1.3** -1.4** -1.6* See text
API5 [NM_006595.2] -1.3† -1.5* n/a
CD74 [NM_001025158.1]1 . 2 * n / a
UCP2 [NM_003355.2]1 . 1 4 * 1 . 8 † ↑[79]
IL6ST [NM_175767.1] -1.3* -1.5† -1.8† n/a
Comparison of CLA interventions and control (Wilcoxon test): *p < 0.05; **p < 0.001; † marks values with a tendency p ≤ 0.1 and more than +/- 
1.5 fold change. Letters a and b indicate significant differences (p < 0.05) between effects in PPARγ2Pro12Pro (Pro; n = 23) and PPARγ2Ala12Ala 
(Ala; n = 11) carriers after the CLA mixture supplementation (Mann-Whitney U test).Lipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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CoA, the building block of fatty acids. CA3 is the most
abundant protein of the rat adipose tissue and its expres-
sion decreased with obesity [25]. CA3 expression was
decreased by leptin but increased by insulin in freshly iso-
lated rat adipose cells, which suggests that the decrease in
CA3 expression observed in obesity may be related to
hyperleptinemia [26]. But in this study a significantly
lower expression of CA3 was detected after t10c12 CLA
compared to control intervention, while there was no
change in leptin expression. These discrepant findings
may be due to the known differences between humans
and rodents [27]. The reduced expression of a key enzyme
in fatty acid synthesis brought about by t10c12 CLA, how-
ever, fits the fat mass reduction observed in other studies
[4].
FASN  (fatty acid synthase) a multifunctional enzyme
complex was significantly induced in carriers of the com-
mon allele after both CLA mixture and t10c12 CLA treat-
ments and also in all subjects combined after t10c12 CLA
treatment. FASN mRNA was up-regulated, leading to
higher insulin concentrations in cultured human adi-
pocytes [28]. Increased expression of FASN in adipose tis-
sues was associated with excess fat accumulation and
impaired insulin sensitivity [29].
SCD (stearoyl-CoA desaturase) is involved in fatty acid
biosynthesis. The enzyme introduces a cis-double bond in
the delta-9 position of certain saturated fatty acids and is
the rate-limiting enzyme in the biosynthesis of monoun-
saturated fatty acids (MUFAs). Studies in animal models
have shown that SCD is highly regulated by diet, but data
in humans are limited [30]. As SCD is involved in the bio-
synthesis of MUFAs, namely palmitoleate (16:1) and
oleate (18:1), the activity of SCD in adipocytes affects the
fatty acid composition of cellular phospholipids, choles-
terol esters and triacylglycerols [31]. In this study SCD
expression was higher after t10c12 CLA supplementation
in all subjects combined and for the rare PPARγ2 genotype
both after CLA mixture and t10c12 CLA treatment. In con-
trast to this Brown et al. [32] found a lower expression in
cultured human preadipocytes after incubation with
t10c12 CLA compared to bovine serum albumin (BSA)
control. Sjogren et al. showed that elevated SCD activity,
measured as fatty acid desaturation index 18:1/18:0 in
human adipose tissue, is closely coupled to the develop-
ment of insulin resistance [33]. Another study however
found no correlation between BMI, insulin sensitivity, tri-
acylglycerol or plasma leptin levels and SCD expression in
subcutaneous adipose tissue [34]. In the same study treat-
ment with the PPARγ agonist pioglitazone increased the
SCD expression and insulin sensitivity in subjects with
impaired glucose tolerance [34]. SCD activity also
increased the concentration of 16:1 and decreased the
concentration of palmitate (16:0). Palmitate is a precursor
of ceramides, which inhibit insulin-stimulated glucose
transport and are involved in development of insulin
resistance [35].
FADS1  (fatty acid desaturase 1) catalyzes endogenous
synthesis of polyunsaturated fatty acids (PUFAs), includ-
ing arachidonic acid and eicosanoids [36], which have,
amongst others, proinflammatory and coagulatory effects.
A higher FADS1 expression as observed in this study in
Pro12Pro carriers and all subjects combined following the
CLA mixture treatment may result in lower triacylglycerol
and fasting insulin levels. Such a correlation was shown
by Steffen et al. [37]. They found an inverse correlation
between FADS1 activity measured as ratio of 20:4,n6/
20:3,n6 and triacylglycerol as well as fasting insulin levels
[37].
Transcription factors
Pro12Pro carriers showed a significantly lower PPARγ
gene expression after CLA mixture treatment, whereas
there was no change in Ala12Ala carriers. Thus the effect
on PPARγ gene expression differed significantly between
the two genotypes. This is the first time that genotype spe-
cific effects of CLA on PPAR gene expression in human
adipose tissue were detected. This might explain some of
the different results obtained in different human studies
investigating the influence of CLA.
Brown et al. showed that c9t11 CLA increased and t10c12
CLA decreased the mRNA expression of PPARγ in primary
human adiopocytes in vitro [32]. Stratifying for PPARγ
isoforms Chung et al. found a suppression of PPARγ and
PPARγ2 at the mRNA and protein level in human cultured
adipocytes after t10c12 CLA incubation [38]. Others,
however, observed an increased expression of PPARγ in
human adipose tissue after 14 weeks of a CLA mixture
treatment [10]. As a key modulator in adipose tissue,
PPARγ controls several genes in lipid and glucose metab-
olism and is involved in the regulation of several genes
affected by CLA treatment (table 2)
[23,34,49,62,64,65,74,79,85-95]. The role of CLA as
PPARγ ligand is not fully understood until now.
Thiazolidinediones (TZDs) - strong synthetic PPARγ ago-
nists used in diabetes therapy to improve insulin sensitiv-
ity - induce weight gain (reviewed in [39]) whereas CLAs,
natural PPARγ ligands, caused moderate weight loss in
humans [4,40] and in some studies reduced insulin sensi-
tivity in an isomer specific way [41,42].
This points out that there are several differing regulatory
mechanisms of CLA and TZDs which are partly PPARγ
independent. These results spur the question if CLA or sin-
gle isomers are either PPARγ agonist or antagonist. In cul-
tured human primary adipocytes t10c12 CLA antagonizedLipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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PPARγ activity ligand-dependently [32,43], whereas
Miller et al. showed that t10c12 CLA is a PPARγ agonist
and that treatment of 3T3-L1 cells with t10c12 CLA
decreases adiponectin through PPARγ-dependent and
PPARγ-independent mechanisms [44].
Very recent studies on PPARγ-DNA binding activity in
human umbilical vein endothelial cells after treatment
with the individual CLA isomers showed that the concen-
tration determines whether CLA isomers exert inhibitory
or a stimulatory effects in inflammatory and atherogenic
processes, and that microenvironments also influence
CLA effects [45]. The tissue dependent differences of
action were also evident in mice; t10c12 CLA induced loss
of adipose tissue but at the same time decreased fatty acid
oxidation and increased fatty acid synthesis in liver [46].
Thus CLA effects depend on concentration, tissue, species,
isomers, and once they are potential PPARγ ligands,
maybe also on PPARγ polymorphisms.
NFAT5 (nuclear factor of activated T-cells 5) refers to the
Rel family of transcription factors, which also comprises
NFκB and NFATc. The exact pathways for NFAT5 regula-
tion are largely unknown. NFAT5 expression was reduced
following CLA mixture and t10c12 CLA treatment. High
glucose concentrations increased binding activity of
NFAT5 to osmotic response elements in both peripheral
blood mononuclear cells and human mesangial cells, and
silencing of NFAT5 reduced expression of aldose reduct-
ase (ADR) [47]. ADR is the first and rate-limiting enzyme
of the polyol pathway where unused glucose is metabo-
lized to sorbitol. ADR expression was associated with
rapid development of diabetic microangiopathy in Japa-
nese Type 2 diabetic patients [48]. However, in our micro-
array experiment ADR gene expression was not affected by
treatments (data not shown).
CREB5 (cAMP responsive element binding protein 5) is
another transcription factor which was less expressed after
t10c12 CLA compared to control treatment in this study.
Little is known about the function of CREB5. It is a mem-
ber of the activating transcription factor 2 cAMP-binding
protein family and is activated by a variety of kinases
including protein kinase A and is involved in tumorigen-
esis of endocrine tissues and different forms of leukemia
[49]. CREB5 was more expressed in omental adipose tis-
sue biopsies of women with metabolic syndrome than in
those of healthy women [50]. The lower expression levels
after t10c12 CLA intervention is rated as a positive effect
on metabolism.
The transcription factor EBF1 (early B-cell factor 1) is up-
regulated during adipocyte differentiation. In mouse adi-
pose tissue Granlund et al. found no change after t10c12
CLA compared to BSA incubation [51]. This is in agree-
ment with our realtime PCR results. We detected only a
slight down regulation in the common genotype after CLA
mixture treatment.
Adipokines
LEP (leptin) reduces fat depots via mediating the degrada-
tion of fatty acids by inducing uncoupling protein 2
(UCP2) and carnitine palmitoyltransferase-1 (CPT1), key
enzymes of β- oxidation [52], by decreasing acetyl-CoA
carboxylase (ACC) [53] and by decreasing food intake
[54]. Leptin, however, induces mitochondrial superoxide
production and MCP1 (monocyte chemotactic protein 1)
expression in endothelial cells [53], endothelial dysfunc-
tion [55] and CRP (C-reactive protein) expression [56].
Effects of CLA on leptin levels are conflicting. In Wistar
rats CLA supplementation decreased serum leptin levels
[57], while no differences were found after CLA supple-
mentation in humans [10].
In this study none of the CLA supplements as compared
to linoleic acid control affected gene expression, which
confirms our microarray results. There was, however, a
genotype specific difference after CLA mixture treatment
as assessed by realtime PCR (Table 2); rare allele carriers
had higher expression levels than PPARγ2 Pro12Pro carri-
ers. Little is known about the functional impact of
Pro12Ala polymorphism on leptin levels in humans. The
lower leptin gene expression after CLA mixture treatment
in subjects with the common genotype are in line with
lower expression levels of PPARγ in this genotype. Same
tendency was found for plasma leptin concentrations in
this study (unpublished data).
Accordingly,  ADIPOQ  (adiponectin) gene expression,
which depends on PPAR regulation, tended to be higher
in rare allele carriers after CLA mixture and t10c12 CLA
treatment (Table 2). While in young Finnish men
Ala12Ala genotype of PPARγ2 was associated with ele-
vated adiponectin level [58], the Ala12Ala allele was asso-
ciated with lower serum adiponectin concentrations in
Japanese men [59]. The same tendency was found in the
MICK cohort [7]. These differing effects of PPARγ2 may be
due to different dietary backgrounds. In the murine 3T3-
L1 cell line, t10c12 CLA compared to a non-stimulated
control decreased adiponectin levels by PPARγ-dependent
and PPARγ-independent mechanisms, whereas c9t11 CLA
showed no effect [44]. In mice higher adiponectin levels
were detected after treatment with pomegranate seed oil,
a rich source of c9t11 CLA [60].
In rare allele carriers NAMPT (visfatin) was significantly
less expressed after t10c12 CLA supplementation com-
pared to control. Plasma visfatin levels were increased in
obese and insulin-resistant humans [61], and plasma lev-Lipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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els and adipocyte gene expression were not affected by
PPARγ ligands [62,63].
Gene expression of the anti-angiogenic adipokine THBS1
(thrombospondin 1) was significantly higher after c9t11
CLA intervention according to our microarray and real-
time PCR results. This adipokine is highly expressed in
subcutaneous adipose tissue of obese and insulin-resist-
ant subjects and is decreased by pioglitazone [64]. On the
other hand, in endothelial cells THBS1 efficacy was
improved by troglitazone through a PPARγ and CD36
dependent mechanism [65], which could result in an anti-
angiogenic action.
Insulin signaling
IGF1  (insulin-like growth factor 1) was less expressed
after t10c12 CLA supplementation in PPARγ2 Pro12 Pro
carriers and all subjects combined, and in PPARγ2 Pro12
Pro carriers the expression was also slightly down regu-
lated after CLA mixture treatment. These results are in line
with findings in human colon cancer cells incubated with
CLA mixture [66]. In adipose tissue IGF1 regulates adipo-
genesis, stimulates lipid oxidation, reduces protein oxida-
tion, and enhances insulin sensitivity in humans [67].
Low serum IGF1 concentrations in humans were associ-
ated with lower visceral but not with lower subcutaneous
or total fat mass [68] and IGF1 and blood glucose levels
were inversely correlated in obesity before and during
energy restriction [69]. These results suggest that lower
expression levels of IGF1 might result in lower insulin
sensitivity after t10c12 CLA treatment, which is in line
with the lower CA3 and higher FASN expression observed
in our study (Table 2).
The expression of GLUT4 (SLC2A4; solute carrier family
2, member 4), another key PPARγ2 target gene, was
enhanced after CLA mixture supplementation compared
to control, suggesting an improved insulin sensitivity. The
effect was somewhat (not significantly) higher in rare
allele carriers alone. In mice a c9t11 CLA-enriched diet
increased adipose tissue plasma membrane GLUT4 and
insulin receptor expression compared with the control
linoleic acid-enriched diet [70]. While c9t11 CLA had no
effect on GLUT4 expression in human preadipocytes [32],
t10c12 CLA repressed GLUT4 in 3T3-L1 cells [18]. This
may explain the induction of insulin resistance by the
t10c12 CLA isomer found in some but not all human tri-
als [71,72]. In our trial HOMA-IR did, however, not dete-
riorate during t10c12 CLA administration compared to
the control (Table 1).
After CLA mixture intervention SORBS1 (sorbin and SH3
domain containing 1) gene expression was lower in
microarray experiment; but realtime PCR confirmed this
result only for the common PPARγ2 genotype. SORBS1
acts as an adaptor protein in the insulin-signaling path-
way. It is partly dissociated from the insulin receptor com-
plex and bound to c-Abl protein upon insulin stimulation
[73]. TZDs, specific synthetic ligands of PPARγ, can
increase the expression of SORBS1 in adipose tissue [74].
Since SORBS1 is a PPARγ target gene, this result is in line
with the lower expression of PPARγ after CLA mixture
intervention in common allele carriers.
By alternative splicing of the PIK3R1  gene (phosphoi-
nositide-3-kinase, regulatory subunit 1 alpha), the phos-
phatidylinositol 3-kinase (PI3K) regulatory subunit
isoforms p85α, p55α and p50α are generated [75]. PI3K
has been shown to regulate most of the insulin action
[76]. Thus the lower gene expression level of PIK3R1 gene
found after CLA mixture supplementation in the common
allele carriers may have counteracted GLUT4 induction.
Taken together the findings of counteracting actions in the
insulin signaling pathway (IGF1, GLUT4, SORBS1,
PIK3R1) (Table 2) may explain why CLA did not alter
insulin sensitivity in our human trial (Table 1).
Other regulated genes
HPGD  (hydroxyprostaglandin dehydrogenase 15-
(NAD)) catalyzes the oxidation reaction prostaglandin E 2
(PGE2) to inactive 15-keto-PGE2 [77], which can act as a
ligand of PPARγ to increase the recruitment of coactiva-
tors. Overexpression of HPGD increased PGE2-dependent
activation of PPARγ in 3T3-L1 adipocytes [77]. In the
present study there were lower expression levels after CLA
mixture supplementation in the rare allele carriers and in
all study subjects combined (Table 2). The Ala12Ala sub-
group showed also significantly lower expression after
t10c12 CLA treatment. Thus the repression of HPGD by
CLA may have weakened PPARγ mediated effects in this
study.
IL6ST (interleukin 6 signal transducer) is shared by many
cytokines, including pro-inflammatory interleukin 6
(IL6). IL6 was shown to induce the plasminogen activator
inhibitor-1 (PAI1) production in cultured human preadi-
pocytes [78]. Rega et al. speculated that IL6, by up-regulat-
ing PAI1 in adipose tissue, might contribute to the
increased cardiovascular risk of patients with obesity and
insulin resistance syndrome due to the auto- or paracrine
actions in human adipose tissue [78]. Thus the repression
of IL6ST after CLA mixture and t10c12 CLA intervention
might indicate counteraction to systemic inflammation.
UCP2, a mitochondrial uncoupling protein that decreases
ATP synthesis coupled to energetic substrates oxidation
expression, was significantly more expressed after CLA
mixture intervention compared to the control. These
results are consistent with those of Ryder et al. who found
higher expression of UCP2 in mice adipose tissue afterLipids in Health and Disease 2009, 8:35 http://www.lipidworld.com/content/8/1/35
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CLA mixture supplementation [2]. They also detected an
up-regulation after c9t11 CLA treatment. TZDs can stimu-
late the expression of UCP2 gene, probably via PPAR
gamma [79]. It was shown that regulation of adiponectin
gene expression is also mediated specifically by mito-
chondrial UCP2 levels [80]. Higher levels of UCP2 were
detected after t10c12 CLA in the PPARγ2 rare allele carriers
(Table 2) and are in line with the fact that adiponectin lev-
els were also higher in these subjects (data not shown).
CD74 showed a higher expression level after CLA mixture
intervention (Table 2). Nothing is known about the func-
tion of CD74 in adipose tissue. In lymphocytes CD74
introduction leads to NFκB activation [81].
API5 (apoptosis inhibitor 5) gene expression was signifi-
cant lower in rare allele carriers after t10c12 CLA treat-
ment (Table 2). API5 was shown to suppress apoptosis
[82]. Suppression of API5, therefore, might mediate the
antitumor effects of CLA found in several studies [83].
Conclusion
CLA intake was shown to reduce BMI and body fat in over-
weight subjects in a number of studies [4]. Up to now, sev-
eral human studies have been published but the effects on
the risk markers of atherosclerosis and on traits of meta-
bolic syndrome were rather inconsistent. Only few data
are available on the effect of individual CLA isomers. This
study provides novel information about the effects exerted
by single CLA isomer intake on several genes as assessed
by genome-wide gene expressions in human adipose tis-
sue, prompting further insights in the mechanism of CLA
action. Furthermore this is the first study in humans
which focused on gene-nutrient interactions with respect
to the PPARγ2 Pro12Ala SNP and CLA isomers.
Only two genes showed significant effects after c9t11 CLA
intervention. This confirms the microarray results from
Murphy et al [84], where there was no significant altera-
tion in gene expression after the incubation of CaCo2 cells
with c9t11 CLA, but plenty of effects after t10c12 CLA
stimulation compared to linoleic acid control.
In summary the intervention with CLA mixture had the
strongest effect on the key enzyme of PUFA synthesis,
FADS1, which may indicate anti-inflammatory and anti-
arteriosclerotic effects. t10c12 CLA showed regulatory
effects on various genes: lower expression levels of CA3
and IGF1 after t10c12 CLA treatment in the whole group
could be a sign for a beginning insulin resistance. On the
other hand, higher expression levels of SCD, a key enzyme
of MUFA synthesis, lower expression of visfatin, the ten-
dency towards higher levels of adiponectin and the reduc-
tion in CREB5 gene expression in rare allele carriers
indicate beneficial effects of t10c12 CLA for this genotype.
The CLA mixture treatment caused significant genotype
specific differences in expression of PPARγ and the PPAR
dependent leptin gene. The fact that the CLA effect on
expression of PPARγ and leptin genes depends on the
PPARγ2 Pro12Ala polymorphism suggests that PPARγ2
contributes to regulatory effects of CLA. The results of the
PPARγ dependent genes, however, do not show a uniform
pattern and interfering factors like HPGD further diversi-
fied response to dietary intervention, reflecting the com-
plexity of interacting regulators.
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